Seeking Research in B cell and Plasma Cell Depletion Programs

CSL is interested in research in the broader area of autoimmunity, with a focus on autoantibody, complement and T cell‑mediated diseases. The focus of this search is on removing or downmodulating the autoimmune component causing disease, while simultaneously preserving protective immunity.

Approaches of Particular Interest

• Antibody‑based Therapeutics
• Bi‑specific (T-cell engaging) Approaches
• Antibody‑Drug Conjugates 
• Biologics
• Tolerance Induction
• Cell and Gene Therapies

Development Stage

• Opportunities at the levels of basic through to late pre‑clinical research 
• Targets validated by patient data, biomarker identification and/or animal models would be advantageous
• Multi-omics data welcomed

Submission Information

One‑page research summaries are encouraged, plus any relevant non‑confidential supporting documents 

Out of Scope

• Research focused on Rheumatoid Arthritis (RA) or Oncology are not of interest. However, Oncology or RA‑related research will be considered if there are broader applications in autoimmunity.
• Small molecule therapeutic approaches are not within scope. RNA/nucleotide therapeutic approaches will be considered, but are not a priority.

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).